The Ohio State University (OSU) and All India Institute for Medical Sciences (AIIMS) hosted the first international H3C Health Sciences Innovation Conference in Mumbai, India, from January 14 to 17, 2015. The session on the nutritional supplement FPP® (Fermented Papaya Preparation) was co-chaired by Prof. Montagnier, 2008 Nobel laureate in Medicine and HIV co-discoverer, and Mr. Hayashi, President of the Osato Research Institute. Three presentations were given: “The Effect of FPP® upon Radiation Exposure” by Prof. Fibach from the Hebrew University, Israel, “The Effect of FPP® in Thalassemia” by Prof. Rachmilewitz from the Wolfson Medical Center, Israel, and “FPP® in the Stimulation of Respiratory Burst Function of Innate Immune Cells in Patients with Type 2 Diabetes” by Dr. Sashwati Roy, Ohio State University. The talks generated an insightful, albeit heated debate about the potential and effects of FPP®.
H3C HEALTH SCIENCES INNOVATION CONFERENCE IN MUMBAI, INDIA
About Author
More info about authorAmélie
After obtaining a Master’s degree in physiology and neurosciences (with distinction) from the University of Lyon, France, in 2008, I worked as a laboratory technologist and engineer at TxCell, a biology company located in Sophia Antipolis, a science and technology hub in the south of France. My research focused on rheumatoid arthritis, Crohn’s disease and the regulatory T cells (Treg) that play a crucial role in preventing autoimmune diseases and are an ideal target for the development of therapies designed to suppress inflammation. I joined the Osato Distribution World Ltd team in 2013. I am in charge of all the scientific documentation used to promote Immun’Âge®, including collaterals, brochures, ads, and more. Responsible for all scientific communication, I keep track of the Osato Research Institute’s on-going studies and inform physicians and customers about our new progress. Feel free to contact me with any questions you may have about our product.
More by Amélie
No Comments so far
Jump into a conversationNo Comments Yet!
You can be the one to start a conversation.